Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
European Journal of Haematology. Supplementum|January 1, 1990
Splenectomy after initial therapy with alpha-IFN in patients with hairy-cell leukemia (HCL): a multi-center study by the Italian Cooperative Group for HCL. Preliminary resultsE E Damasio, M Federico, A Frassoldati, et al.
Leukemia & Lymphoma|April 1, 1995
ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL)V Silingardi, M Federico, L Cavanna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?P Carlini, A Frassoldati, S De Marco, et al.
American Journal of Clinical Oncology|December 22, 1999
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized studyG Cocconi, G Bisagni, M Bella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi ExperienceP G Gobbi, C Pieresca, A Frassoldati, et al.
Haematologica|May 18, 1999
Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL)G Longo, C Fiorani, S Sacchi, et al.
Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised studyM Colozza, G Bisagni, A M Mosconi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2012
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month resultsR Coleman, R de Boer, H Eidtmann, et al.
European Journal of Cancer (Oxford, England : 1990)|November 28, 2017
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry studyA Musolino, F Falcini, A Sikokis, et al.
Pageof 4